Antioxidant drug shows promise for kids with NF1

NCT ID NCT04481048

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether N-acetylcysteine (NAC), an antioxidant drug, can improve motor skills and learning in children with neurofibromatosis type 1 (NF1). Twenty-five children aged 8 to 16 took NAC or a placebo for 8 weeks. The goal was to see if NAC is safe and helps with movement and attention problems common in NF1.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

N-acetylcysteine (NAC)

What this could lead to

If it works, this could point toward a treatment for motor and learning problems in children with NF1.

What could go wrong

This is a small, early-phase trial with only 25 participants. Results may not apply to all children with NF1, and the treatment may not show benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States